Also trades as: NAMS (NASDAQ) · $vol 27M
NAMSW NASDAQ
NewAmsterdam Pharma Company N.V.
1W: -14.9%
1M: -19.7%
3M: -48.5%
YTD: -60.4%
1Y: -62.5%
3Y: +435.1%
5Y: +1207.1%
$9.15
+0.90 (+10.91%)
Weekly Expected Move ±17.8%
$6
$7
$9
$11
$12
Credit Risk of going bust: lower than 96% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), NewAmsterdam Pharma Company N.V. would be worth roughly what it owes.
Total debt $82K against a stock market value of $2.40B.
Distance to default 20.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $41K (short-term plus half of long-term), stock volatility 53.3%; Altman Z'' 8.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $82K against a stock market value of $2.40B.
Distance to default 20.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $41K (short-term plus half of long-term), stock volatility 53.3%; Altman Z'' 8.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.5B
52W Range8.25-30.45
Volume18
Avg Volume943
Beta0.11
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Harvey Davidson Facp.
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-10
Websitenewamsterdampharma.com
Gooimeer 2-35
Naarden, NH 1411 DC
NL
Naarden, NH 1411 DC
NL
31 35 206 2971
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Latest News
NewAmsterdam Pharma Company N.V. Estimates – NASDAQ:NAMSW - TradingView
(NAMSW) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
Madison Square Garden Sports Corp. (MSGS) Slips 1.20% as Shares Trade Near $402 - Diagonal Spread Trade - https://www.dars.gov.et/
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| LANGE LOUIS G | S-Sale | 44,173 | $30.41 | 2026-03-11 |
| LANGE LOUIS G | S-Sale | 446 | $31.23 | 2026-03-11 |
| LANGE LOUIS G | X-InTheMoney | 44,619 | $11.50 | 2026-03-09 |
| LANGE LOUIS G | X-InTheMoney | 44,619 | $11.50 | 2026-03-09 |
| Kastelein Johannes J | M-Exempt | 101,409 | — | 2026-03-09 |